F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer. Diagnostic procedures, such as FES imaging, may help predict how well patients will respond to hormone therapy and may help plan the best treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173

Estrogen Receptor Positive Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7

TERMINATED NA

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103

Estrogen Receptor Positive Primary or Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7

ACTIVE_NOT_RECRUITING PHASE2

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

NCT02398773

HER2/Neu Negative Progesterone Receptor Negative Progesterone Receptor Positive +1 more

ACTIVE_NOT_RECRUITING PHASE2

Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer

NCT01627704

Metastatic Breast Cancer

COMPLETED NA

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

NCT02409316

Estrogen Receptor Positive Breast Cancer Breast Neoplasm Metastatic Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Estimate the ability of \[\^18F\] FES positron emission tomography (PET) or PET/computed tomography (CT) uptake at the level of standard uptake value (SUV) \< 1.5 to predict overall response (OR) to first line endocrine therapy for metastatic breast cancer.

SECONDARY OBJECTIVES:

I. Evaluate the independent role of \[\^18F\] FES in predicting response and time to progression in patients treated with first-line endocrine therapy for metastatic breast cancer.

II. Examine the role of \[\^18F\] FES in predicting OR or clinical benefit (CB), in concert with tissue assay of levels of estrogen receptor (ER) messenger ribonucleic acid (mRNA) measured using quantitative polymerase chain reaction (PCR), and semi-quantitative interpretation of estrogen receptor (ER), progesterone receptor (PgR), androgen receptor (AR), and human epidermal growth factor-2 (HER2), in addition to serial measures of hormone levels in plasma.

III. Evaluate the relationships among \[\^18F\] FES, semi-quantitative ER from immunohistochemistry (IHC), and ER mRNA as measured by quantitative PCR.

IV. Document the safety profile of \[\^18F\] FES PET in newly diagnosed patients with metastatic breast cancer.

V. Evaluate FES SUV \< 1.5 as the optimal cutpoint for predicting OR to first-line endocrine therapy for metastatic breast cancer.

VI. Estimate the rate of \[\^18F\] FES SUV \< 1.5 in newly diagnosed metastatic breast cancer patients planning a course of endocrine therapy.

OUTLINE:

Patients undergo \[\^18F\] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to \[\^18F\] FES PET scan.

After completion of study treatment, patients are followed up for at least 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Estrogen Receptor-positive Breast Cancer Progesterone Receptor-negative Breast Cancer Progesterone Receptor-positive Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (FES)

Patients undergo \[\^18F\] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to \[\^18F\] FES PET scan.

Group Type EXPERIMENTAL

F-18 16 alpha-fluoroestradiol

Intervention Type RADIATION

Undergo \[\^18F\] FES PET

fludeoxyglucose F 18

Intervention Type RADIATION

Undergo standard clinical FDG PET/CT

positron emission tomography

Intervention Type PROCEDURE

Undergo \[\^18F\] FES PET

positron emission tomography

Intervention Type PROCEDURE

Undergo standard clinical FDG PET/CT

computed tomography

Intervention Type PROCEDURE

Undergo standard clinical FDG PET/CT

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

F-18 16 alpha-fluoroestradiol

Undergo \[\^18F\] FES PET

Intervention Type RADIATION

fludeoxyglucose F 18

Undergo standard clinical FDG PET/CT

Intervention Type RADIATION

positron emission tomography

Undergo \[\^18F\] FES PET

Intervention Type PROCEDURE

positron emission tomography

Undergo standard clinical FDG PET/CT

Intervention Type PROCEDURE

computed tomography

Undergo standard clinical FDG PET/CT

Intervention Type PROCEDURE

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

F-18 FES fluorine-18 16 alpha-fluoroestradiol 18FDG FDG FDG-PET PET PET scan tomography, emission computed FDG-PET PET PET scan tomography, emission computed tomography, computed

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients will have pathologically confirmed invasive breast cancer with clinical, radiographic and/or pathologic evidence of stage IV disease; patients must have tissue blocks available from biopsy of at least one site of metastatic disease and/or from diagnosis of their primary breast cancer
* Disease may be measurable (by Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) or non-measurable but must be present in at least one non-liver site and imageable on FDG PET scan; in patients with non-measurable disease by RECIST criteria, one of the following may be used to assess and follow disease: MUC-1 antigen level (either cancer antigen \[CA\] 27.29 or carcinoembryonic antigen \[CEA\]) \> 2 x upper limit of normal (ULN), Circulating tumor cell assay \> 5, or FDG-PET SUV \> 2.5 in purely lytic lesions; elevated tumor markers alone are insufficient
* No prior endocrine therapy for breast cancer or

* Off adjuvant endocrine therapy for \> 6 months or
* Greater than 2 years of a single adjuvant endocrine therapy at the time of first recurrence and plan to change to alternate endocrine therapy; use of tamoxifen must be discontinued 6-8 weeks prior to entrance into the study
* Prior chemotherapy regimens in the adjuvant or neoadjuvant setting are allowed
* Women treated with adjuvant LHRH (luteinizing hormone-releasing hormone) analog are eligible
* Be assessed for menopausal status; for study purposes, postmenopausal is defined as:

* A prior documented bilateral oophorectomy, or
* A history of at least 12 months without spontaneous menstrual bleeding, or
* Age 60 or older with a prior hysterectomy without oophorectomy, or
* Age less than 60 with a prior hysterectomy without oophorectomy (or in whom the status of the ovaries is unknown), with a documented follicle stimulating hormone (FSH) level demonstrating confirmatory elevation in the postmenopausal range for the lab
* Premenopausal patients must have a baseline FSH, and estradiol levels to determine menopausal status; measures will be repeated at 3-6 months to confirm menopausal status
* Patients must be positive for estrogen receptor (ER) and may or may not be positive for progesterone receptor (PgR) by IHC in the primary tumor and/or metastatic site; the pathology report for assay of ER will be reviewed by one of the investigators prior to enrollment, the study pathologist will review the pathology report if necessary for determination of study eligibility
* Tumor HER2/neu expression must be determined prior to study enrollment; assessment may be by fluorescence in situ hybridization (FISH) assay or by immunohistochemistry (ICC); if determination is intermediate by ICC, FISH must be performed
* Life expectancy \> 16 weeks
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)
* Absolute neutrophil count (ANC) \>= 1,000
* Platelet count \>= 50,000
* Hemoglobin within normal limits (WNL) for the institution
* Serum creatinine =\< 1.5 x institutional ULN (IULN) and estimated creatinine clearance \> 50 mL/min using the Cockroft-Gault formula
* Bilirubin =\< 1.5 x ULN
* Serum glutamic oxaloacetic transaminase (SGOT)/ serum glutamic pyruvate transaminase (SGPT) =\< 1.5 x ULN
* Alkaline phosphatase =\< 2.5 x ULN
* Patients must be planning a course of endocrine therapy with one of the following: tamoxifen +/- ovarian suppression, aromatase inhibitor +/- fulvestrant (with ovarian suppression in pre-menopausal patients) or fulvestrant alone
* After entry into the study, patients are expected to be followed for at least 6 months after the injection of \[\^18F\] FES
* Have a negative pregnancy test within 7 days prior to registration if of childbearing potential
* No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years
* Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific screening procedures
* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Exclusion Criteria

* Patients with a history of prior endocrine therapy for metastatic disease are NOT eligible; adjuvant endocrine therapy for \< 2 years total or discontinued less than 6 months before first disease recurrence also excludes the patient
* Patients with disease in the liver only are NOT eligible for the study
* Patients who are HER2/neu positive disease and planning to undergo HER2-directed therapy (trastuzumab or lapatinib) are NOT eligible for the study
* Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded
* Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases
* History of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent
* Any other life-threatening illness (e.g., serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)
* Unwillingness to give informed consent
* Medically unstable as judged by the patient's physician
* Psychological, familial, sociological, or geographical conditions which do not permit compliance with the study protocol
* Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion
* Patient weight greater than 400 lbs (exceeds weight limit for tomograph table)
* Uncontrolled diabetes mellitus (fasting glucose \> 200 mg/dL)
* Adult patients who require monitored anesthesia for PET scanning

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janet F Eary, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Radiology, University of Alabama, Birmingham, AL

David A Mankoff, MD, PhD

Role: STUDY_DIRECTOR

University of Pennsylvania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Washington Medical Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. A phase 2 study of 16alpha-[18F]-fluoro-17beta-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30.

Reference Type RESULT

PMID: 24170452 (View on PubMed)